Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government shutdown may soon conclude.
CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level.
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement.
The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit.
Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing.
